The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer

Yongnan Li, Yoichi Mizutani, Takumi Shiraishi, Terukazu Nakamura, Kazuya Mikami, Natsuki Takaha, Koji Okihara, Akihiro Kawauchi, Toshiyuki Sakai, Tsuneharu Miki

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To measure dihydropyrimidine dehydrogenase (DPD), an enzyme involved in the metabolism of 5-fluorouracil (5-FU), expression in prostate cancer and determine whether 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of DPD, enhances the antitumoral activity of 5-FU against prostate cancer. PATIENTS, MATERIALS AND METHODS: In all, 44 prostate tissue specimens were obtained from men who had a radical prostatectomy alone for prostate cancer, and 38 specimens from men who had had neoadjuvant hormonal therapy. We analysed the cancerous tissue and normal prostate tissue for DPD expression using immunohistochemistry, and determined its prognostic significance. In cultured human prostate cancer lines (DU145 and LNCaP), we compared the cytotoxicity of 5-FU/CDHP with that of 5-FU alone. Finally, in experiments on immunodeficient mice, we studied the effect of oral administration of tegafur, a pro-drug for 5-FU, with or without CDHP on the growth of tumours introduced by injection of DU145 cells. RESULTS: The expression of DPD was significantly higher in cancerous than normal prostate tissue; 36 of 44 (82%) specimens of prostate cancer expressed DPD, whereas only 25 of 44 (57%) specimens of normal prostate tissue expressed DPD. For men with prostate cancer who had radical prostatectomy alone, men with negative DPD expression tended to have a longer recurrence-free survival than those with positive expression; there were no recurrences in men with prostate cancer and negative DPD expression in the 5-year follow-up. DPD expression was significantly lower in men with prostate cancer who received neoadjuvant hormonal therapy. In vitro treatment of human prostate cancer cell lines with 5-FU/CDHP showed more cytotoxicity than with 5-FU treatment alone. Finally, DU145 tumours in mice treated with tegafur and CDHP were significantly smaller than in mice given tegafur alone. CONCLUSION: The present study showed that DPD expression is elevated in prostate cancer, and indicate that DPD inhibitors might enhance the antitumour activity of 5-FU against prostate cancer.

Original languageEnglish (US)
Pages (from-to)663-668
Number of pages6
JournalBJU International
Volume99
Issue number3
DOIs
Publication statusPublished - Mar 2007
Externally publishedYes

    Fingerprint

Keywords

  • 5-FU
  • DPD
  • Immunohistochemistry
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Li, Y., Mizutani, Y., Shiraishi, T., Nakamura, T., Mikami, K., Takaha, N., ... Miki, T. (2007). The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer. BJU International, 99(3), 663-668. https://doi.org/10.1111/j.1464-410X.2006.06606.x